Sign In
Buy TXG
$31.75
-0.470 (-1.46%)
At Close: Jun 16, 2026
10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit
08:00am, Friday, 06'th Aug 2021
PLEASANTON, Calif., Aug. 06, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summi
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2021 Results - Earnings Call Transcript
11:21pm, Wednesday, 04'th Aug 2021
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q2 2021 Results - Earnings Call Transcript
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
07:50pm, Wednesday, 04'th Aug 2021
10x Genomics (TXG) delivered earnings and revenue surprises of 61.54% and 2.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad
06:30am, Tuesday, 27'th Jul 2021
Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes
10x Genomics to Report Second Quarter Financial Results on August 4, 2021
04:03pm, Wednesday, 07'th Jul 2021
PLEASANTON, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the second quarter 2021 after market close on Wednesday, August 4t
These 3 Cathie Wood Stocks Are Still Going Strong
05:35am, Friday, 25'th Jun 2021
Even with some setbacks in 2021, the ARK Invest manager has still found some winners.
High-Growth Stocks Come Back Into Investors' Favor
08:18pm, Wednesday, 23'rd Jun 2021
The short-term bottom for next-generation enterprises is in, and high multiple stocks are returning to investors' favor.
10x Genomics: Promising Growth From A Life Science Leading Single Cell Specialist
12:52am, Monday, 31'st May 2021
10x Genomics, Inc. is a global life sciences technology company developing innovative biological products from their cross-functional expertise across biology, chemistry, software, and hardware with a
Here's Why 10x Genomics Can't Satisfy Short-Term Investors
01:06pm, Saturday, 29'th May 2021
Long-term investors should keep perspective.
Strength Seen in 10x Genomics (TXG): Can Its 3.9% Jump Turn into More Strength?
06:01am, Friday, 28'th May 2021
10x Genomics (TXG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Down More Than 20%, Is This Cathie Wood Biotech A Buy?
06:50am, Thursday, 20'th May 2021
10x Genomics stock has fallen, despite announcing strong first-quarter numbers.
Recap: 10x Genomics Q1 Earnings
08:49am, Thursday, 13'th May 2021
Shares of 10x Genomics (NASDAQ:TXG) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share rose 186.96% over the past year to $0.66, which beat the estimate of
Why Investors Didn't Like 10x Genomics' Q1 Results
06:04am, Thursday, 06'th May 2021
The company delivered tremendous revenue growth but a deteriorating bottom line.
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates
10:10pm, Wednesday, 05'th May 2021
10x Genomics (TXG) delivered earnings and revenue surprises of 56.00% and 2.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q1 2021 Results - Earnings Call Transcript
08:48pm, Wednesday, 05'th May 2021
10x Genomics, Inc. (TXG) CEO Serge Saxonov on Q1 2021 Results - Earnings Call Transcript
